The pharmaceutical industry is aggressively evolving, with increasing demand for high-performance Active Pharmaceutical Ingredients (APIs). Dulaglutide, a GLP-1 receptor agonist, represents example of this trend. To address this demand, US-based manufacturing services are gaining traction. These